Averix Bio

Big news from Averix Bio!

Our Drug Master File (DMF) # MF036798 has been issued by the US Food & Drug Administration, US FDA, for our API phytocannabinoid CBD Isolate!

Averix Bio continues to set the compliance standard within the cannabis industry. This submission reinforces our commitment to supplying the highest quality ingredients for commercial applications, research, and clinical trials within the pharmaceutical, veterinary, cosmetics, and nutraceutical markets.

Compliance, consistency, and manufacturing rigor are the components that separate good products from great products. At Averix, great API ingredients are the core of our business. That's what sets us apart.
We look forward to talking with you about how Averix Bio is the ingredient supplier you've been looking for. We'll help you take your products to the next level. See our full press release below and reach out to learn more! [email protected]

Press Release: https://lnkd.in/dqSSaKk2


**p

Averix is honored to be chosen by Alterola Biotech, a U.K.-based pharmaceutical company, to provide our API Phytocannabinoid CBD Isolate for their research, development, and manufacturing operations.

The company is focused on harnessing the therapeutic potential of cannabinoids and similar compounds to bring safe and efficacious treatments to seriously ill patients. In its news release announcing the agreement, Tim Rogers, Executive Chairman of Alterola Biotech, said “We are excited at the opportunity for Averix Bio to supply Alterola with GMP-compliant Active Pharmaceutical Ingredients (APIs) for our existing portfolio of cannabinoid development candidates.”

Learn more here: https://lnkd.in/gSZ2P-Wq

If you're ready to talk to a Tier One cannabinoid ingredient supplier you can trust, please get in touch with us at [email protected] or +1 252.220.0887, and let's start the conversation.



**p

If you want to know what it takes to help ensure that your customers can and will trust that your products contain safe and efficacious cannabinoid ingredients of the highest quality, read this post from our CEO, Miles Wright, and learn what cGMP 210/211 compliance is and why it must be a critical component of your supply chain:

READ NOW | https://averixbio.com/why_cgmp_matters/

And if you're looking for a 21 CFR Part 210 and Part 211 cGMP-compliant API Phytocannabinoid isolate, look no further. We successfully completed an independent audit by the ProPharma Group in October and are ready to be your trusted partner and Tier One supplier. Get in touch with us at [email protected] or +1 252.220.0887, and let's start the conversation.

**p

Averix Bio is submitting a DMF for our CBD isolate to the in Q4 2021. What will that mean for you? In short, you’ll be able to partner with a 21 CFR PART 210 and PART 211 cGMP compliant supplier of botanical-based API for your pre-clinical/clinical research and medical therapies you bring to the global patient market. Come talk with us at the Summit in Boston next week and learn more.

Will's pharmaceutical experience spans nearly 50 years, with tenure at multinational companies like Burroughs Wellcome, , , , , and . He understands FDA Quality Systems Regulations, cGMPs, ISO Quality Systems standards, and ICH guidelines. He has both hosted and performed numerous FDA and third-party audits over the years. You can read Will’s thoughts about “The Q Word: What Quality Means at Averix Bio” in this post: https://averixbio.com/the-q-word/

21 CFR Part 210 and Part 211 cGMP-compliant.
That means you can TRUST our botanical-based CBD isolate.
And that means you can TRUST Averix Bio.

Visit us during the Summit and learn about our 21 CFR Part 210 and Part 211 cGMP-compliant . We're ready to partner with you on early- to late-phase studies and therapeutic products for patients. https://www.averixbio.com